Reuters logo
BRIEF-Shanghai Fosun Pharmaceutical Group unit passes FDA approval for new drug clinical trail
September 8, 2017 / 10:01 AM / in a month

BRIEF-Shanghai Fosun Pharmaceutical Group unit passes FDA approval for new drug clinical trail

Sept 8(Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd :

* Says its controlling subsidiary Henlix, Inc received FDA approval for HLX06 clinical trial from U.S Food and Drug Administration

* HLX06 is used for solid tumors treatment

* Henlix will be able to launch clinical trail of its HLX06 in U.S after receiving the FDA approval

Source text in Chinese: goo.gl/cbbVew

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below